Drug Profile


Alternative Names: 589C; 589C80; BW 589C; BW 589C80; BW A589C

Latest Information Update: 24 Aug 1999

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Benzaldehydes; Benzoic acids
  • Mechanism of Action Immunostimulants; Th1 cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C; HIV infections; Malignant melanoma; Sickle cell anaemia

Most Recent Events

  • 24 Aug 1999 Discontinued-II for Sickle cell anaemia in United Kingdom (PO)
  • 24 Aug 1999 Discontinued-II for Malignant melanoma in United Kingdom (Unknown route)
  • 24 Aug 1999 Discontinued-II for Hepatitis B in Spain (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top